EAM Investors’s ALX Oncology ALXO Stock Holding History

EAM Investors’s Portfolio ALXO Stock Details ALXO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-19,645	Closed	-$1.69M	–	331
2020 Q4	$1.69M	Buy	+19,645	New	+$1.18M	0.28%	169

Other funds holding ALXO

venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return

Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM Investors's ALXO Position: Q1 2021 in Review

EAM Investors sold out of ALX Oncology (ALXO) in Q1 2021, closing a stake of 19,645 shares — an estimated $1.69M sold.

EAM Investors first reported a position in ALXO in Q4 2020 and held it in 1 quarter. The position peaked at $1.69M in Q4 2020. 93 funds tracked by Wall St. Rank hold ALXO as of Q1 2021.

EAM Investors reported no remaining ALX Oncology position as of Q1 2021 after selling out during the quarter.
EAM Investors sold 19,645 ALX Oncology shares in Q1 2021, an estimated $1.69M.
EAM Investors first reported a position in ALX Oncology in Q4 2020 and held it in 1 quarter.
EAM Investors's ALX Oncology position peaked at $1.69M in Q4 2020.
93 funds tracked by Wall St. Rank held ALX Oncology as of Q1 2021.

Based on EAM Investors's 13F filing for Q1 2021, filed 11 May 2021.